With the precision of monoclonal antibodies and the potency of small-molecular payloads, antibody-drug conjugates (ADC) are promising cancer therapeutics. As of this year, there are 19 ADC drugs ...

Antibody Drug Conjugates (ADCs) are a class of small molecule drugs (also known as a payload) and an antibody conjugated together by a chemical linker. ADCs are designed to target specific cells, such ...

AstraZeneca is once again teaming up with Hungarian artificial intelligence specialist Turbine as it looks to speed up and gain deeper insights into its antibody-drug conjugate discovery process.

Antibody-drug conjugates (ADCs) are typically composed of a monoclonal antibody attached to a cytotoxic drug via a chemical linker. The antibody is able to identify biomarkers on and attach to cancer ...

This novel approach utilizes cysteine-engineered antibodies which allows for the development of uniform and homogenous ADCs with precise control of the drug to antibody ratio (DAR). The drug-payload, ...

Antibody-drug conjugates (ADCs) constitute a rapidly evolving class of targeted oncology therapeutics that couple tumor-selective antibodies with highly potent cytotoxins. At the 16th Annual World ADC ...

In the chemical world, the tiny hyphen in antibody-drug conjugates—or ADCs, as they’re commonly known—does a lot more work than the perfunctory punctuation suggests. That hyphen stands for the ...

Dr. Paolo Tarantino discusses the importance of strategic sequencing and drug-specific prophylaxis to optimize ADC therapy in breast cancer. The rise of antibody-drug conjugates (ADCs) has transformed ...